Minireviews
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Sep 24, 2023; 14(9): 335-342
Published online Sep 24, 2023. doi: 10.5306/wjco.v14.i9.335
Advances in drug resistance of triple negative breast cancer caused by pregnane X receptor
Zhou-Zhou Rao, Zhong-Wen Tang, Jie Wen
Zhou-Zhou Rao, Department of Physiology, Hunan Normal University School of Medicine, Changsha 410003, Hunan Province, China
Zhong-Wen Tang, Jie Wen, Department of Pediatric Orthopedics, Hunan Provincial People’s Hospital, the First Affiliated Hospital of Hunan Normal University, Changsha 410013, Hunan Province, China
Author contributions: Rao ZZ did the literature search and wrote the paper; Tang ZW revised the paper; Wen J conceived and coordinated the study, designed; Tang ZW and Wen J contribute equally to this study, they share co-corresponding author.
Supported by Science project of Hunan Provincial Health Commission, No. B202304089304.
Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jie Wen, PhD, Assistant Professor, Department of Pediatric Orthopedics, Hunan Provincial People’s Hospital, the First Affiliated Hospital of Hunan Normal University, No. 61 West Jiefang Rd, Changsha 410013, Hunan Province, China. cashwj@qq.com
Received: June 21, 2023
Peer-review started: June 21, 2023
First decision: August 10, 2023
Revised: August 17, 2023
Accepted: August 29, 2023
Article in press: August 29, 2023
Published online: September 24, 2023
Processing time: 90 Days and 13.2 Hours
Abstract

Breast cancer is the most common malignancy in women worldwide. Triple-negative breast cancer (TNBC), refers breast cancer negative for estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2, characterized by high drug resistance, high metastasis and high recurrence, treatment of which is a difficult problem in the clinical treatment of breast cancer. In order to better treat TNBC clinically, it is a very urgent task to explore the mechanism of TNBC resistance in basic breast cancer research. Pregnane X receptor (PXR) is a nuclear receptor whose main biological function is to participate in the metabolism, transport and clearance of allobiological agents in PXR. PXR plays an important role in drug metabolism and clearance, and PXR is highly expressed in tumor tissues of TNBC patients, which is related to the prognosis of breast cancer patients. This reviews synthesized the important role of PXR in the process of high drug resistance to TNBC chemotherapeutic drugs and related research progress.

Keywords: Triple-negative breast cancer; Pregnane X receptor; Drug resistance; Cytochrome P450; Uridinediphosphate glucuronyl transferases; Glutathione transferases; ATP-binding cassette transporter

Core Tip: Treatment of triple-negative breast cancer (TNBC) is a difficult problem in the clinical treatment of breast cancer. It is a very urgent task to explore the mechanism of TNBC resistance in basic breast cancer research. Pregnane X receptor (PXR) is a nuclear receptor whose main biological function is to participate in the metabolism, transport and clearance of allobiological agents in PXR. This reviews synthesized the important role of PXR in the process of high drug resistance to TNBC chemotherapeutic drugs and related research progress.